HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
MONDAY, Oct. 30, 2017 (HealthDay News) -- Data on methods used for assessing minimal residual disease (MRD) in multiple myeloma (MM) are presented in a report published online Oct. 23 in the International Journal of Laboratory Hematology.
Irina V. Galtseva, from the Ministry of Healthcare of the Russian Federation in Moscow, and colleagues discussed the use of new diagnostic methods for MRD detection in MM.
The researchers note that response to treatment and prediction of recurrence can be assessed more reliably using new diagnostic methods, including allele-specific polymerase chain reaction, new-generation sequencing, and multicolor flow cytometry, which allow detection of MRD with sensitivity of 10−5 to 10 −6. Multiflow cytometry is nonstandardized, and its sensitivity and specificity depend on monoclonal antibody panel, characteristics of flow cytometers, and strategies for gating. Increasing the numbers of antigens analyzed and using at least eight-color flow cytometry enables highly specific and accurate analysis, resulting in sensitivity of about 0.001 percent.
"It has been demonstrated that MRD in MM patients is potentially achievable and is an important independent prognostic factor. Thus, MRD testing is essential in assessing treatment effectiveness at different stages of treatment and in future can help take adequate decisions at the stage of maintenance therapy after HDCT [high-dose chemotherapy] and also design individual treatment protocols," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 29, 2022